Roche SA

Grenzacherstrasse 124, 4070 Basel
Roche SA   link
Lieu: Bâle
Domaine: Pharmacologie
Pharmacologie - Santé - 11.11
Roche today announced data from the phase II NOBILITY study, investigating the safety and efficacy of Gazyva (obinutuzumab) for adults with proliferative lupus nephritis. 1 The study met the primary endpoint with Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrating superiority compared to placebo plus standard of care.
Pharmacologie - Sciences de la vie - 11.11

Roche today announced positive data from the pivotal Part 2 of SUNFISH, a study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study met its primary endpoint of change from baseline in the Motor Function Measure 32 (MFM-32) scale after one year of treatment with risdiplam, compared to placebo.

Pharmacologie - Santé - 30.10

Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis European Medicines Agency (EMA) grants Accelerated Assessment for satralizumab application Roche announced today that

Santé - Pharmacologie - 18.10

Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have co

Pharmacologie - Santé - 30.09

Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer.

Pharmacologie - Santé - 6.11

Ten Roche medicines will be featured in more than 70 abstracts and 21 oral presentations, across a range of 15 blood cancers and non-malignant haematological conditions New data for CD20-CD3 bispecific cancer immunotherapies confirms their potential in difficult-to-treat lymphomas Long-term data

Pharmacologie - Santé - 21.10

First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration, the E

Pharmacologie - Santé - 14.10

Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris.

Santé - Pharmacologie - 30.09

Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of t

website preview


Médecine et sciences de la vie